Antibody that binds to OX40 and use thereof

A technology of antibody and monoclonal antibody, which is applied in the field of cancer and infectious diseases, and the treatment of OX40-related diseases, can solve the problem of reducing Treg activity and achieve good anti-tumor effect in vivo

Active Publication Date: 2019-08-02
BEIJING MABWORKS BIOTECH
View PDF68 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it has also been reported that high doses of agonistic OX40 antibodies successfully reduce Treg activity through the apoptotic program, thereby blocking Treg-mediated suppression (Voo et al., (2013) Immunol.191(7): 3641- 3650)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody that binds to OX40 and use thereof
  • Antibody that binds to OX40 and use thereof
  • Antibody that binds to OX40 and use thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0122] Preparation of monoclonal antibody of the present invention

[0123] The monoclonal antibodies of the present invention can be prepared using the somatic cell hybridization (hybridoma) technique of Kohler and Milstein (1975) Nature 256:495. Other embodiments for producing monoclonal antibodies include viral or oncogenic transformation of B lymphocytes and phage display techniques. Chimeric or humanized antibodies are also well known in the art. See, eg, US Patents 4,816,567; 5,225,539; 5,530,101; 5,585,089; 5,693,762 and 6,180,370.

[0124] Generation of Transfectomas to Produce Monoclonal Antibodies of the Invention

[0125] Antibodies of the invention can also be produced in host cell transfectomas using, for example, recombinant DNA techniques combined with gene transfection methods (eg Morrison, S. (1985) Science 229:1202). In one embodiment, DNA encoding partial or full-length light and heavy chains obtained by standard molecular biology techniques is insert...

Embodiment 1

[0167] Example 1 Construction of HEK293A cell strain stably expressing human, monkey or mouse OX40

[0168] cDNA sequences encoding human, monkey or mouse OX40 (SEQ ID NOs: 31, 33 and 35, respectively encoding amino acid sequences SEQ ID NOs: 32, 34 and 36) were synthesized and cloned into pLV-EGFP(2A) -Puro vector (Beijing Yingmao Shengye Biotechnology Co., Ltd., China). The resulting pLV-EGFP(2A)-Puro-OX40, psPAX and pMD2.G plasmids were transfected into HEK293T cells (Nanjing Kebai Company, China) by lipofection to produce lentiviruses. The method is completely consistent with the instructions of Lipofectamine 3000 (Thermo Fisher Scientific, USA). Three days after transfection, lentivirus was harvested from the cell culture medium (DMEM medium (Cat#: SH30022.01, Gibco) supplemented with 10% FBS (Cat#: FND500, Excell)) of HEK293T cells. Then HEK293A cells (Nanjing Kebai Company, China) were transfected with lentivirus to obtain HEK293A cells stably expressing human, monk...

Embodiment 2

[0169] Example 2 Preparation of hybridoma cell lines secreting human OX40 antibody

[0170] Mouse anti-human OX40 monoclonal antibody was obtained by conventional hybridoma fusion technique with slight modification of the protocol.

[0171] inoculation

[0172] Twenty BALB / C mice (Victoria, China) were cross-injected with recombinant human OX40(ECD)-hFc protein (SinoBiological, CN, Cat#: 10481-H08H) and monkey OX40-hFc protein (Cat#: 90846 -C08H, Yiqiao Shenzhou, China) for immunization, the specific immunization process is shown in Table 2. Human OX40(ECD)-hFc protein and monkey OX40-hFc protein were treated with equal volume of complete Freund's adjuvant (Cat#: F5881-10*10ML, Sigma, USA) or incomplete Freund's adjuvant (Cat#: F5506-6* 10ML, Sigma, USA) or PBS phacoemulsification.

[0173] Table 2. Immunization schedule

[0174]

[0175] One week after each booster immunization, 50 μl serum was taken from each mouse, and the titer was detected by ELISA, using recom...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides an isolated monoclonal antibody that specifically binds to human OX40. Also provided are nucleic acid molecules encoding the antibody, an expression vector, a host celland a method for expressing the antibody. The invention also provides immunoconjugates, bispecific molecules, chimeric antigen receptors, oncolytic viruses, and pharmaceutical compositions comprisingthe antibody, as well as methods of treatment using the antibody of the invention.

Description

technical field [0001] The present invention relates to an antibody specifically binding to human OX40, its preparation and use, especially its use in treating diseases related to OX40, such as cancer and infectious diseases. Background technique [0002] The T cell co-stimulatory receptor OX40, also known as CD134, TNFRSF4, and ACT35, is a member of the tumor necrosis factor receptor superfamily. It enhances T-cell responses triggered by TCR and is mainly expressed on the surface of activated T cells, including CD4+ T cells, CD8+ T cells and regulatory T cells (Treg) (Redmond et al., (2009) Crit. Rev. Immunol. 29(3): 187-201; Jensen et al., (2010) Semin. Oncol. 37(5): 524-532). Unlike CD28, OX40 is not expressed on naive T cells, but peaks in expression between 12 hours and 5-6 days after antigen stimulation. Its ligand, OX40L, exhibits the same pattern and can be detected on the surface of antigen-presenting cells 1-3 days after antigen exposure (Willoughby et al., (2017...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C12N15/13A61K39/395A61P31/00A61P35/00A61P37/04
CPCA61K2039/505A61P31/00A61P35/00A61P37/04C07K16/2878C07K2317/24C07K2317/33C07K2317/76C07K2317/92A61K31/513A61K31/555A61K31/704A61K45/06A61K2039/585C07K2317/75A61K31/282A61K31/7115A61K35/00A61K2039/55533A61K2039/55561A61K39/001118C07K16/2818C07K16/2827
Inventor 胡稳奇李江美江伦李锋
Owner BEIJING MABWORKS BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap